L'intérêt à découvert pour Clorox donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Clorox. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Clorox (NYSE:CLX) Stock, Rapport sur les intérêts à découvert

CLOROX COMPANY

Clorox

Since its start more than 100 years ago, Clorox has expanded to operate in a variety of consumer products categories, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. More than 80% of Clorox's sales come from its home turf.

Clorox Co

Calix Ltd

COLLEXIS HOLDINGS INC by Collexis Holdings, Inc.

JP Morgan analyst Andrea Teixeira maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and lowers the price target from $144 to $140.

News

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Clorox, Lowers Price Target to $140

Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) has accused IT services provider Cognizant Technology Solutions Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>) of gross negligence and breach of trust after a cyberattack caused widespread disruption and nearly <a target="_blank" href="https://www.benzinga.com/news/23/09/34689201/why-clorox-stock-is-sliding-monday" rel="noreferrer noopener">$380 million in damages</a>.
According to Clorox, the root cause of the attack was Cognizant's failure to follow basic cybersecurity protocols it had agreed to uphold under a <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">long-standing partnership</a>.
For more than a decade, Clorox relied on Cognizant to operate its employee service desk, including tasks such as password recovery and credential resets.
Also Read: <a href="https://www.benzinga.com/news/earnings/25/05/45209366/clorox-stock-drops-after-worse-than-expected-q3-results-heightened-macroeconomic-uncertainties-lowered-sales-ceo-says" target="_blank" rel="noreferrer noopener">Clorox Stock Drops After Worse-Than-Expected Q3 Results: &#8216;Heightened Macroeconomic Uncertainties&#8217; Lowered Sales, CEO says</a>
The responsibility came with a clear requirement: no credentials would be reset without properly authenticating the requester. Despite repeated assurances, Cognizant allegedly failed to follow these procedures.
Cognizant did not immediately respond to Benzinga&#8217;s request for comment.
On Aug. 11, 2023, a cybercriminal contacted the Cognizant-run service desk and was given direct access to Clorox's network credentials without facing any authentication checks.
This lapse happened multiple times that day, giving the attacker unfettered access to the company's systems. Clorox says audio recordings show Cognizant handing over credentials with no verification.
<ul class="wp-block-list">
<li>Cybercriminal: I don't have a password, so I can't connect.</li>
<li>Cognizant Agent: Oh, ok. Ok. So let me provide the password to you ok?</li>
<li>Cybercriminal: Alright. Yep. Yeah, what's the password?</li>
<li>Cognizant Agent: Just a minute. So it starts with the word "Welcome…</li>
</ul>
The cyberattack that followed crippled Clorox's corporate network, disrupted its supply chain, and significantly impaired its ability to fulfill orders.
According to the lawsuit <a target="_blank" href="https://www.documentcloud.org/documents/26025404-clorox-versus-cognizant-complaint/" rel="noreferrer noopener">filed</a> by Clorox, Cognizant's mishandling of the initial credential requests was compounded by a botched incident response and disaster recovery effort, further worsening the damage.
Clorox maintains that Cognizant ignored the company's clearly outlined security procedures, which were designed to prevent exactly such an attack.
Despite touting its cybersecurity expertise and claiming to have trained its service desk staff in these protocols, Cognizant's actions—or inactions—revealed what Clorox called a "devastating lie."
The company says the breach could have been entirely avoided with proper training and adherence to security protocols.
Instead, Clorox was left dealing with over $49 million in direct recovery costs and hundreds of millions more in business interruption losses.
Meanwhile, Cognizant reported $20 billion in revenue in 2024, with no apparent hit to its brand or bottom line.
CTSH Price Action:&nbsp;Cognizant Tech Solns shares were up 0.72% at $77.34 on Wednesday,&nbsp;<a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">according to Benzinga Pro.</a> The stock is trading within its 52-week range of $65.52 to $90.82.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46565953/lockheed-martin-confirms-talks-with-us-over-trumps-175-billion-golden-dome-missile-shield-ceo-james-taiclet-says-no-contracts-yet-lmt-is-all-in" target="_blank" rel="noreferrer noopener">Lockheed Martin Confirms Talks With US Over Trump&#8217;s $175 Billion &#8216;Golden Dome&#8217; Missile Shield — CEO James Taiclet Says No Contracts Yet, LMT Is &#8216;All In&#8217;</a></li>
</ul>
Image via Mdisk/Shutterstock

Legal

Movers

Trading Ideas

General

CTSH

Clorox Claims Cognizant Handed Credentials To Hacker, Ignored Security Protocols

WASHINGTON, July 22 (Reuters) - Bleach maker Clorox <a href="https://workspace.refinitiv.com/web/apps/quotewebapi?RIC=CLX.N">CLX.N</a>said Tuesday that it has sued information technology provider Cognizant <a href="https://workspace.refinitiv.com/web/apps/quotewebapi?RIC=CTSH.O">CTSH.O</a> over a devastating 2023 cyberattack, alleging that the hackers pulled off the intrusion simply by asking the tech company's staff for employees' passwords.
Clorox was one of several major companies hit in August 2023 by the hacking group dubbed <a href="reuters://REALTIME/verb=NewsStory/ric=nL4N3AV3OE">Scattered Spider</a>, which specializes in tricking IT help desks into handing over credentials and then using that access to lock them up for ransom. The group is often described as unusually sophisticated and persistent, but in a case filed in California state court on Tuesday, Clorox said one of Scattered Spider's hackers was able to repeatedly steal employees' passwords simply by asking for them.
"Cognizant was not duped by any elaborate ploy or sophisticated hacking techniques," according to a copy of the <a href="https://www.documentcloud.org/documents/26025404-clorox-versus-cognizant-complaint/">lawsuit</a> reviewed by Reuters. "The cybercriminal just called the Cognizant Service Desk, asked for credentials to access Clorox's network, and Cognizant handed the credentials right over."
Cognizant did not immediately return a message seeking comment on the suit, which was not immediately visible on the public docket of the Superior Court of Alameda County. Clorox provided Reuters with a receipt for the lawsuit from the court.
Three partial transcripts included in the lawsuit allegedly show conversations between the hacker and Cognizant support staff in which the intruder asks to have passwords reset and the support staff complies without verifying who they are talking to, for example by quizzing them on their employee identification number or their manager's name.
"I don't have a password, so I can't connect," the hacker says in one call. The agent replies, "Oh, ok. Ok. So let me provide the password to you ok?"
The 2023 hack caused $380 million in damages, Clorox said in the suit, about $50 million of which were tied to remedial costs and the rest of which were attributable to Clorox's <a href="reuters://REALTIME/verb=NewsStory/ric=nL4N3BA3M5">inability to ship products to retailers</a> in the wake of the hack.
Clorox said the clean-up was hampered by other failures by Cognizant's staff, including failure to de-activate certain accounts or properly restore data.
&nbsp;

'Lawsuit says Clorox hackers got passwords simply by asking'- Reuters

UBS analyst Peter Grom maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and lowers the price target from $150 to $134.

UBS Maintains Neutral on Clorox, Lowers Price Target to $134

Barclays analyst Lauren Lieberman maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Underweight and lowers the price target from $129 to $119.

Barclays Maintains Underweight on Clorox, Lowers Price Target to $119

Wells Fargo analyst Chris Carey maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Equal-Weight and lowers the price target from $142 to $135.

Wells Fargo Maintains Equal-Weight on Clorox, Lowers Price Target to $135

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>JP Morgan cut Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) price target from $240 to $230. JP Morgan analyst Samik Chatterjee maintained an Overweight rating. Apple shares closed at $201.56 on Wednesday. S<a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">ee how other analysts view this stock</a>.</li>
<li>Jefferies cut the price target for The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) from $167 to $145. Jefferies analyst Kaumil Gajrawala maintained a Buy rating. Clorox shares closed at $119.48 on Wednesday. <a href="https://www.benzinga.com/quote/CLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity raised Worthington Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) price target from $69 to $81. Canaccord Genuity analyst Brian McNamara maintained a Buy rating. Worthington shares closed at $61.35 on Wednesday. <a href="https://www.benzinga.com/quote/WOR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co boosted the price target for Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) from $54 to $60. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. Kymera Therapeutics shares closed at $46.47 on Wednesday. <a href="https://www.benzinga.com/quote/KYMR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut the price target for The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) from $74 to $68. Wells Fargo analyst Alec Brondolo downgraded the stock from Overweight to Equal-Weight. Trade Desk shares closed at $69.80 on Wednesday. <a href="https://www.benzinga.com/quote/TTD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup raised Truist Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) price target from $44 to $55. Citigroup analyst Keith Horowitz upgraded the stock from Neutral to Buy. Truist Financial shares settled at $41.40 on Wednesday. <a href="https://www.benzinga.com/quote/TFC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) price target from $172 to $200. Rosenblatt analyst Kevin Cassidy maintained a Buy rating. Micron shares closed at $127.25 on Wednesday. <a href="https://www.benzinga.com/quote/MU/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham increased Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) price target from $320 to $377. Needham analyst Joseph Stringer maintained a Buy rating. Alnylam Pharmaceuticals shares closed at $321.94 on Wednesday.  <a href="https://www.benzinga.com/quote/ALNY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark boosted the price target for Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from $350 to $475. Benchmark analyst Mickey Legg maintained a Buy rating. Tesla shares settled at $327.55 on Wednesday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird increased Concentrix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) price target from $62 to $72. Baird analyst David Koning maintained an Outperform rating. Concentrix shares closed at $54.17 on Wednesday. <a href="https://www.benzinga.com/quote/CNXC/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/TSLA/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="570" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410-1024x570.png" alt="" class="wp-image-963276" style="width:623px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410-1024x570.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410-768x428.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410.png 1162w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46093486/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Utilities Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

Markets

AAPL

ALNY

CNXC

KYMR

TSLA

Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday

Jefferies analyst Kaumil Gajrawala maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Buy and lowers the price target from $167 to $145.

Jefferies Maintains Buy on Clorox, Lowers Price Target to $145

Clorox Professional (CloroxPro), the trusted makers of a broad portfolio of healthcare and commercial cleaning solutions, is proud to announce our new contract with Vizient, the nation's largest provider-driven healthcare performance improvement company. This new agreement reflects CloroxPro's commitment to supporting healthcare and cleaning professionals with expanded solutions to meet evolving needs.\
"CloroxPro is eager to bring our 110-year legacy of supporting healthcare professionals to Vizient as we collaborate to deliver exceptional value to their customers," said Dan Kellenberger, General Manager and VP, Clorox Professional. "We are committed to supporting healthcare professionals' dedication to combatting infections by providing cleaning and disinfecting solutions that deliver efficacy and value, as well as education and support for our customers and end-users at every step of their journey."
Under the new Vizient contract, CloroxPro will be providing a broad range of cleaning and disinfecting solutions, including products from trusted brands like Clorox Healthcare, Clorox EcoClean, Pine-Sol and more. The contract is effective as of May 1, 2025, with both companies working closely to ensure a seamless integration of the expanded product offerings.

Contracts

CloroxPro Enters New Agreement With Vizient To Supply Multiple Cleaning And Disinfecting Products

Barclays analyst Lauren Lieberman maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Underweight and lowers the price target from $134 to $129.

Barclays Maintains Underweight on Clorox, Lowers Price Target to $129

Wall Street edged lower by midday Tuesday as uncertainty surrounding trade policies lingered, with investors adopting a cautious approach ahead of <a href="https://www.benzinga.com/topic/federal-reserve">Wednesday&#8217;s Federal Reserve meeting.</a>
In a meeting with Canadian Prime Minister Mark Carney, President Donald Trump suggested the U.S. may soon begin renegotiating the USMCA. He noted that China is eager to negotiate due to its struggling economy, driven by a lack of U.S. trade, but emphasized the talks would take place &#8220;at the right time.&#8221;
Trump kept his trade stance unclear, suggesting that while some agreements may be signed, there is no obligation to finalize any, and dismissed repeated questions about the number of deals in progress.
The S&amp;P 500 dipped 30 points, or 0.6%, to 5,610, on track for its second consecutive negative session after nine straight gains. The Nasdaq 100 dropped 0.8%, while the Russell 2000 slipped 1%.
Ten of the 11 S&amp;P 500 sectors were in the red, with utilities as the only sector in the green. The U.S. dollar fell, extending its losses for a third straight session.
Commodities saw a broad rally, with oil prices surging 3.6%, pushing WTI above $59, following <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45224883/oil-soars-above-59-as-middle-east-airstrikes-jolt-markets">Israeli airstrikes in Yemen</a>. Gold also rallied, climbing 2.4% to above $3,400 per ounce amid heightened geopolitical tensions.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) reversed Monday's gains, slipping 0.4% to $94,375.
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,614.65</td>
<td>-0.6%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,905.06</td>
<td>-0.8%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,796.10</td>
<td>-0.9%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,983.93</td>
<td colspan="2">-1.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:55 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.7% to $559.24.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.8% to $409.01.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 0.9% to $481.23.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) tumbled 1.1% to $196.68.</li>
<li>The&nbsp;Utilities&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, up 1.2%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 2.4%.</li>
</ul>
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
Stocks reacting to earnings reports included: 
<ul>
<li>Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) up 2.70%</li>
<li>The Clorox Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) down 2.31%</li>
<li>Coterra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) down 9.95%</li>
<li>Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) down 13.9%</li>
<li>Diamondback Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) down 0.53%</li>
<li>Realty Income Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) down 0.68%</li>
<li>The Williams Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) down 5.19%</li>
<li>Celanese Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) up 9.14%</li>
<li>Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) down 7.37%</li>
<li>Lattice Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) down 13.6%</li>
<li>Mattel Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) up 3.61%</li>
<li>Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) down 13.6%</li>
<li>Duke Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) up 2.24%</li>
<li>Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) up 10.94%</li>
<li>TransDigm Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) down 5.67%</li>
<li>Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) up 1.26%</li>
<li>Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) down 3.32%</li>
<li>American Electric Power Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) up 0.52%</li>
<li>Marathon Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) up 0.37%</li>
<li>Fidelity National Information Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) down 2.88%</li>
<li>WEC Energy Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) up 0.77%</li>
<li>Gartner, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) up 1.14%</li>
<li>IQVIA Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) down 1.32%</li>
<li>Archer-Daniels-Midland Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) up 2.02%</li>
<li>Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) down 4.43%</li>
<li>Leidos Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) up 4.11%</li>
<li>Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) down 1.43%</li>
<li>GlobalFoundries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) down 3.57%</li>
<li>Expeditors International of Washington, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPD#NYSE">EXPD</a>) down 3.67%</li>
<li>Ball Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) up 0.55%</li>
<li>Jacobs Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) down 5.56%</li>
</ul>
Stocks slated to report earnings after the close include: Assurant Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>), Arista Networks Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>), Gen Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>), Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), International Flavors &amp; Fragrances Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>), Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>), Mosaic Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>), Corpay Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>), Wynn Resorts Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>), Jack Henry &amp; Associates Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JKHY#NASDAQ">JKHY</a>), Devon Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>), Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), Coty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) and Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>).
Read now: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45205780/sp-500-stocks-that-defy-sell-in-may-myth-5-companies-with-strong-historical-gains">S&amp;P 500 Stocks That Defy &#8216;Sell In May&#8217; Myth: 5 Companies With Strong Historical Gains</a></li>
</ul>
Photo: Gumbariya via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Government

Large Cap

Macro Economic Events

Mid Cap

Regulations

Sector ETFs

Broad U.S. Equity ETFs

Commodities

Small Cap

Global

Econ #s

Economics

ETFs

$BTC

ANET

BALL

COTY

CPAY

CTRA

SPDR Dow Jones Industrial Average ETF Trust

EXPD

FANG

JKHY

LDOS

LSCC

PLTR

RIVN

SMCI

VRTX

WYNN

Select Sector SPDR-Consumer Discretionary

Stocks Fall On Trade Concerns, Oil And Gold Rally: What's Driving Markets Tuesday?

Morgan Stanley analyst Dara Mohsenian maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Equal-Weight and lowers the price target from $165 to $150.

Morgan Stanley Maintains Equal-Weight on Clorox, Lowers Price Target to $150

Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) posted weaker-than-expected third-quarter results after <a href="https://www.benzinga.com/quote/CLX/earnings">Monday&#8217;s closing bell</a>.
Clorox reported quarterly earnings of $1.45 per share, which missed the analyst consensus estimate of $1.57. Quarterly revenue came in at $1.67 billion, which missed the analyst consensus estimate of $1.73 billion and is down from revenue of $1.81 billion from the same period last year.
"In the third quarter, heightened macroeconomic uncertainties drove changes in shopping behaviors, resulting in temporary category slowdowns and lower sales. We expect these slowdowns to persist in the fourth quarter, as reflected in our updated outlook," said CEO Linda Rendle.
Clorox affirmed its fiscal 2025 adjusted EPS guidance of $6.95 to $7.35 per share, versus the $7.12 analyst estimate. The company narrowed its fiscal year revenue outlook from a range of $7.02 billion to $7.24 billion to a range of $7.02 billion to $7.09 billion, below the $7.1 billion estimate.
Clorox shares fell 0.5% to close at $138.39 on Monday.
These analysts made changes to their price targets on Clorox following earnings announcement.
<ul>
<li>JP Morgan analyst Andrea Teixeira maintained Clorox with a Neutral and lowered the price target from $151 to $144.</li>
<li>Wells Fargo analyst Chris Carey maintained Clorox with an Equal-Weight rating and lowered the price target from $145 to $142.</li>
</ul>
Considering buying CLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="578" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06093032/image-55-1024x578.png" alt="" class="wp-image-903314" style="width:560px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06093032/image-55-1024x578.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06093032/image-55-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06093032/image-55-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06093032/image-55.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Earnings

Clorox Analysts Slash Their Forecasts After Downbeat Results

Wells Fargo analyst Chris Carey maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Equal-Weight and lowers the price target from $145 to $142.

Wells Fargo Maintains Equal-Weight on Clorox, Lowers Price Target to $142

JP Morgan analyst Andrea Teixeira maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and lowers the price target from $151 to $144.

JP Morgan Maintains Neutral on Clorox, Lowers Price Target to $144

WIIM

Clorox shares are trading lower after the company reported worse-than-expected Q3 financial results and narrowed its FY25 sales guidance below estimates.

Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) released its third-quarter results after Monday's closing bell. Here's a look at the key figures<a href="https://www.benzinga.com/pressreleases/25/05/n45206776/clorox-reports-q3-fiscal-year-2025-results-updates-outlook"> from the report.&nbsp;</a>
The Details:&nbsp;Clorox reported quarterly earnings of $1.45 per share, which missed the analyst consensus estimate of $1.57. Quarterly revenue came in at $1.67 billion, which missed the analyst consensus estimate of $1.73 billion and is down from revenue of $1.81 billion from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/earnings/25/05/45194998/saudi-arabias-oil-power-play-jolts-markets-can-diamondback-and-rivals-survive-the-squeeze?utm_source=articleShare">Saudi Arabia&#8217;s Oil Power Play Jolts Markets: Can Diamondback And Rivals Survive The Squeeze?</a>
The company reported gross margin&nbsp;increased 240 basis points to 44.6% from 42.2% in the year-ago quarter, primarily driven by cost savings and the benefits from the divestitures of the VMS and&nbsp;Argentina&nbsp;businesses.
&#8220;In the third quarter, heightened macroeconomic uncertainties drove changes in shopping behaviors, resulting in temporary category slowdowns and lower sales. We expect these slowdowns to persist in the fourth quarter, as reflected in our updated outlook,&#8221; said CEO&nbsp;Linda Rendle.&nbsp;
Outlook:&nbsp;Clorox affirmed its fiscal 2025 adjusted EPS guidance of&nbsp;$6.95 to $7.35&nbsp;per share, versus the $7.12&nbsp;analyst estimate. The company narrowed its fiscal year revenue outlook from a range of&nbsp;$7.02 billion to $7.24 billion&nbsp;to&nbsp;a range of $7.02 billion to $7.09 billion, below the $7.1 billion&nbsp;estimate.
CLX Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Clorox stock was down 4.06% after-hours at $132.77 on Monday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/management/25/05/45180224/these-ev-makers-could-shine-if-musk-leaves-tesla?utm_source=articleShare">These EV Makers Could Shine If Musk Leaves Tesla</a></li>
</ul>
Image: Shutterstock

Clorox Stock Drops After Worse-Than-Expected Q3 Results: 'Heightened Macroeconomic Uncertainties' Lowered Sales, CEO says

Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) raises FY2025 GAAP EPS guidance from $5.52-$5.92 to $5.73-$6.13 vs $5.64 analyst estimate..

Guidance

Clorox Raises FY2025 GAAP EPS Guidance from $5.52-$5.92 to $5.73-$6.13 vs $5.64 Est

Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) affirms FY2025 Adj EPS guidance from $6.95-$7.35 to $6.95-$7.35 vs $7.12 analyst estimate. Narrows FY2025 sales outlook from $7.02 billion-$7.24 billion to $7.02 billion-$7.09 billion vs $7.10 billion estimate.

Clorox Affirms FY2025 Adj EPS Guidance of $6.95-$7.35 vs $7.12 Est; Narrows FY2025 Sales Guidance from $7.02B-$7.24B to $7.02B-$7.09B vs $7.10B Est

Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) reported quarterly earnings of $1.45 per share which missed the analyst consensus estimate of $1.57 by 7.64 percent. This is a 15.2 percent decrease over earnings of $1.71 per share from the same period last year. The company reported quarterly sales of $1.67 billion which missed the analyst consensus estimate of $1.73 billion by 3.36 percent. This is a 8.05 percent decrease over sales of $1.81 billion the same period last year.

Comments

Clorox

Intérêt court

Clorox (NYSE:CLX) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL